MCI-196
Phase 3Small molecule
Tanabe Pharma CorporationMCI-196 is one of 73 small molecule programs targeting Hyperphosphatemia. It is currently in Phase 3.
3
Indications
8
Total Trials
0
Active Trials
72
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
885 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1MCI-196
Tanabe Pharma CorporationPhase 3
NOVOLIN R
Novo NordiskPreclinical
Glargine
Eli LillyPreclinical
Sulfonylureas
Eli LillyPreclinical
SGLT-2 Inhibitor
SSheffield Teaching Hospitals NHS Foundation Trust
Preclinical
Blank Control
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Preclinical
Insulins
Eli LillyPreclinical
Dipeptidyl Peptidase-4 Inhibitors
Boehringer IngelheimPreclinical
Biasp 30
Novo NordiskPreclinical
Glucagon-Like Peptide-1 (GLP-1)
Novo NordiskPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Kidney Disease4 trials
Hyperphosphatemia3 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MCI-196. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company